Loading clinical trials...
Loading clinical trials...
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing techno...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Verve Therapeutics, Inc.
NCT07473960 · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT06568601 · Hypercholesterolemia
NCT00353782 · Hypercholesterolemia, Atherosclerosis
NCT07489209 · Homozygous Familial Hypercholesterolemia (HoFH)
NCT07037771 · Homozygous Familial Hypercholesterolemia
Clinical Study Center
Adelaide
Clinical Study Center
Melbourne
Clinical Study Center
Chicoutimi
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions